The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors
Open accessAbstract
Most of the dual nano drug delivery systems fail to enter malignant brain tumors due to a lack of proper targeting systems and the size increase of the nanoparticles after drug conjugation. Therefore, a triple conjugated system was developed with carbon dots (C-dots) which has an average particle size of 1.5–1.7 nm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990
Nanoparticle-based theranostic agents
Xie, J., Lee, S., & Chen, X. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.009 · Cited by 1,422
Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery
Cheng, R., Meng, F., Deng, C., Klok, H.-A., & Zhong, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.084 · Cited by 1,354
Du, J.-Z., Du, X.-J., Mao, C.-Q., & Wang, J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja207150n · Cited by 1,172
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
Self-citationMulti-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.013 · Cited by 776
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Luissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., & Couraud, P.-O. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-23 · Cited by 654
P-glycoprotein Inhibition for Optimal Drug Delivery
Amin, M. L. (2013) · Drug Target Insights · doi:10.4137/dti.s12519 · Cited by 624
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Parhi, P., Mohanty, C., & Sahoo, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.010 · Cited by 573
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Qian, Z., Ma, J., Shan, X., Feng, H., Shao, L., & Chen, J. (2014) · Chemistry – A European Journal · doi:10.1002/chem.201304374 · Cited by 486
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Koshy, M., Villano, J. L., Dolecek, T. A., Howard, A., Mahmood, U., Chmura, S. J., Weichselbaum, R. R., & McCarthy, B. J. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0738-7 · Cited by 481
Recent advances in bioapplications of C-dots
Zhao, A., Chen, Z., Zhao, C., Gao, N., Ren, J., & Qu, X. (2015) · Carbon · doi:10.1016/j.carbon.2014.12.045 · Cited by 380
Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Sturm, D., Pfister, S. M., & Jones, D. T. W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0242 · Cited by 339
Introduction to Nanoscience and Nanotechnology
Hornyak, G. L., Tibbals, H. F., Dutta, J., & Moore, J. J. (2008) · CRC Press eBooks · doi:10.1201/9781420047806 · Cited by 262
Li, S., Amat, D., Peng, Z., Vanni, S., Raskin, S., De Angulo, G., Othman, A. M., Graham, R. M., & Leblanc, R. M. (2016) · Nanoscale · doi:10.1039/c6nr05055g · Cited by 228
Self-citationCancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes
Pardo, J., Peng, Z., & Leblanc, R. (2018) · Molecules · doi:10.3390/molecules23020378 · Cited by 226
Self-citationMulti-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapy
Wu, Y.-F., Wu, H.-C., Kuan, C.-H., Lin, C.-J., Wang, L.-W., Chang, C.-W., & Wang, T.-W. (2016) · Scientific Reports · doi:10.1038/srep21170 · Cited by 208
Nontoxic Carbon Dots Potently Inhibit Human Insulin Fibrillation
Li, S., Wang, L., Chusuei, C. C., Suarez, V. M., Blackwelder, P. L., Micic, M., Orbulescu, J., & Leblanc, R. M. (2015) · Chemistry of Materials · doi:10.1021/cm504572b · Cited by 197
Self-citationCombinatorial Drug Conjugation Enables Nanoparticle Dual‐Drug Delivery
Aryal, S., Hu, C. J., & Zhang, L. (2010) · Small · doi:10.1002/smll.201000631 · Cited by 183
Kumari, S., Ahsan, S. M., Kumar, J. M., Kondapi, A. K., & Rao, N. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06888-4 · Cited by 162
Carbon dots: promising biomaterials for bone-specific imaging and drug delivery
Peng, Z., Miyanji, E. H., Zhou, Y., Pardo, J., Hettiarachchi, S. D., Li, S., Blackwelder, P. L., Skromne, I., & Leblanc, R. M. (2017) · Nanoscale · doi:10.1039/c7nr05731h · Cited by 159
Self-citationLai, I. P.-J., Harroun, S. G., Chen, S., Unnikrishnan, B., Li, Y., & Huang, C. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.01.062 · Cited by 153
Declines in Cancer Death Rates Among Children and Adolescents in the United States, 1999-2014.
Curtin, S. C., Miniño, A., & Anderson, R. N. (2016) · PubMed · Cited by 146
Li, S., Peng, Z., & Leblanc, R. M. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01451 · Cited by 126
Self-citationHanafi‐Bojd, M. Y., Jaafari, M. R., Ramezanian, N., Xue, M., Amin, M., Shahtahmassebi, N., & Malaekeh‐Nikouei, B. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.009 · Cited by 112
Shen, J., Gao, F., Yin, T., Zhang, H., Ma, M., Yang, Y., & Feng, Y. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.01.009 · Cited by 110
Matai, I., Sachdev, A., & Gopinath, P. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b02095 · Cited by 96
Wu, L., Luderer, M. J., Yang, X., Swain, C., Zhang, H., Nelson, K., Stacy, A. J., Shen, B., Lanza, G. M., & Pan, D. (2013) · Theranostics · doi:10.7150/thno.6535 · Cited by 89
Particle Carriers for Combating Multidrug-Resistant Cancer
Yan, Y., Björnmalm, M., & Caruso, F. (2013) · ACS Nano · doi:10.1021/nn405632s · Cited by 89
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells
Zhang, R., Saito, R., Shibahara, I., Sugiyama, S., Kanamori, M., Sonoda, Y., & Tominaga, T. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1968-x · Cited by 32
Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells
Villodre, E. S., Kipper, F. C., Silva, A. O., Lenz, G., & Lopez, P. L. D. C. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0611-6 · Cited by 32
Khalilian, M. H., Mirzaei, S., & Taherpour, A. A. (2016) · Journal of Molecular Modeling · doi:10.1007/s00894-016-3133-7 · Cited by 18
Tariq, M., Alam, A., Singh, A. T., Panda, A. K., & Talegaonkar, S. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1136713 · Cited by 16
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“successively reported the development of two CDs-based nanocarriers to treat glioblastoma brain tumor and Alzheimer’s disease.(307,308) The CDs for brain tumor treatment were conjugated with transferrin, epirubicin, temozolomide via EDC/NHS reactions with carboxylic groups on CDs surface.”
MethodHersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Mansuriya, B. D., & Altintas, Z. (2021) · Nanomaterials · doi:10.3390/nano11102525 · Cited by 438
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
Su, S., & M. Kang, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090837 · Cited by 259
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Metadata
- Authors
- Hettiarachchi, S. D., Graham, R. M., Mintz, K. J., Zhou, Y., Vanni, S., Peng, Z., & Leblanc, R. M.
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 11
- Issue
- 13
- Pages
- 6192-6205
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- OpenAlex
- W2918597707
- Cited by
- 294
- References
- 40
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
